Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp50 | Acromegaly and GH | ECE2019

Sleep disorders and cognitive dysfunction in acromegaly

Dassie Francesca , Wennberg Alexandra , Lorusso Riccardina , Parolin Matteo , Russo Lucia , Mazzocut Sara , Benavides-Varela Silvia , De Carlo Eugenio , Martini Chiara , Vettor Roberto , Semenza Carlo , Maffei Pietro

Background: In the general population, sleep disorders are associated with an increased risk of cognitive impairment; moreover, people with dementia often have sleep disturbances. The prevalence of sleep disorders, such as sleep apnea, in acromegalic patients is higher than in the general population, and they may have a higher risk of cognitive impairment due to acromegaly treatment (i.e. Radiotherapy) or cardiovascular comorbidities. In the literature, data about the relation...

ea0063p256 | Pituitary and Neuroendocrinology 1 | ECE2019

Hyperglycemia and pasireotide lar in acromegaly: a study with continuous glucose monitoring

Russo Lucia , Mazzocut Sara , Dassie Francesca , Parolin Matteo , Martini Chiara , Carlo Eugenio De , Fallo Francesco , Mioni Roberto , Vettor Roberto , Maran Alberto , Maffei Pietro

Background: Pasireotide LAR is a multireceptor targeted somatostatin analogue that has been shown to obtain a better biochemical control of acromegaly. However, pasireotide LAR could induce hyperglycemia in acromegalic patients with higher baseline glucose values. The devices that can track interstitial glucose levels such as continuous glucose monitoring (CGM) could be a useful for studying the impact of SSA on patientsÂ’ glucose status.Aim: We aime...

ea0063p1101 | Pituitary and Neuroendocrinology 3 | ECE2019

Pegvisomant: daily versus non daily administration a single centre real life study

Dassie Francesca , Rosson Marco , Parolin Matteo , Russo Lucia , Mazzocut Sara , Martini Chiara , De Carlo Eugenio , Mioni Roberto , Fallo Francesco , Vettor Roberto , Maffei Pietro

Background: Pegvisomant (PEG) is a second line medical treatment for active acromegalic patients. PEG efficacy is between 61.5 and 92% and even if it is administered daily its long half-life suggests a possible use with a non-daily regime.Aim: We aim to compare acromegalic patients on daily PEG administration (DP) with patients on non-daily PEG administration (NDP).Methods: We studied 43 acromegalic patients under PEG treatment bet...